Yes—I agree 100% that peer review is of great value to the medical community and patient community. The forthcoming DCVax peer review will have a significant impact and will be the most reliable source in advance of FDA advisory.
Dr. Liau has authored over 170 peer-reviewed research articles, along with several book chapters, and a textbook entitled Brain Tumor Immunotherapy. She is on the editorial boards of several scientific/medical journals and was the Editor-in-Chief of the Journal of Neuro-Oncology (2007–2017).
"Peer review has been the foundation of scholarly publishing and scientific communication since the 1665 publication of the Philosophical Transactions of the Royal Society. The benefits and advantages of peer review in scientific research, and particularly medical research, are manifold and manifest."
Dr. Liau will be presenting DCVax at the annual Society for Neuro-Oncology meeting in November.
“The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education.”
“The annual SNO meeting is the academic and educational nexus for the latest findings from all neuro-oncology subspecialties and disciplines.”
Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial
Plenary Abstract Presenter: Linda M. M. Liau, MD PhD - University of California, Los Angeles
Market Data 
Markets 
AI
